DDInter513 DDInter782
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Dexamethasone {u} (Compound) resembles {v} (Compound) Fludrocortisone
Dexamethasone {u} (Compound) resembles {v} (Compound) Triamcinolone
Dexamethasone {u} (Compound) treats {v} (Disease) psoriatic arthritis
Dexamethasone {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Dexamethasone {u} (Compound) upregulates {v} (Gene) PCYOX1L
Dexamethasone {u} (Compound) palliates {v} (Disease) kidney cancer
Dexamethasone {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Dexamethasone {u} (Compound) downregulates {v} (Gene) DNAJB6
Dexamethasone {u} (Compound) causes {v} (Side Effect) Vitreous opacities
Dexamethasone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium bicarbonate
Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Dexamethasone (Compound) resembles Triamcinolone (Compound)
Dexamethasone (Compound) treats psoriatic arthritis (Disease)
Dexamethasone (Compound) binds CYP3A7-CYP3A51P (Gene)
Dexamethasone (Compound) upregulates PCYOX1L (Gene)
Dexamethasone (Compound) palliates kidney cancer (Disease)
Dexamethasone (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Dexamethasone (Compound) downregulates DNAJB6 (Gene)
Dexamethasone (Compound) causes Vitreous opacities (Side Effect)
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate